Advancing HIV treatment: The impact of a global therapeutics network

National Institutes of Health (NIH) investments over recent decades in the Advancing Clinical Therapeutics Globally (ACTG) network have helped to transform human immunodeficiency virus (HIV) from a deadly infection to a chronic disease. The ACTG has expanded global clinical trial capacity and trained generations of physician-scientists engaged in clinical and translational research. With a structure that integrates a scientific leadership group, statistical and laboratory centers, and community engagement, with dedicated clinical sites, the ACTG has produced impactful, guideline-changing research, engaged in extensive interdisciplinary collaborations, and influenced several areas of HIV-related science. This review highlights the ACTG's contributions to HIV therapeutics and related infections, demonstrating the value of this investment and serving as a model for future approaches to help address other chronic diseases.